Astellas to end license agreement with Janssen for ASP015K inhibitor
Astellas will regain all rights granted to Janssen after termination and the company is considering future plan for ASP015K outside Japan. The company will continue the phase III
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
The acquired site, through its enhanced manufacturing capabilities, will help Johnson to meet increasing demand for custom pharmaceutical services and active ingredients. Johnson Matthey fine chemicals division director
Novartis had been granted exclusive license in 2010, to develop and commercialize binimetinib. Designed specifically for cancer patients, the binimetinib is currently advancing in three Phase 3 clinical